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CBackground: A recent indirect comparison study showed that
sunitinib-refractory metastatic renal cell carcinoma (mRCC) patients
treatedwith everolimus are expected to have improved overall survival
outcomes compared to patients treated with sorafenib. This analysis
examines the likely cost-effectiveness of everolimus versus sorafenib
in this setting from a US payer perspective.Methods: AMarkovmodel
as developed to simulate a cohort of sunitinib-refractory mRCC pa-
ients and to estimate the cost per incremental life-years gained (LYG)
nd quality-adjusted life-years (QALYs) gained.Markov states included
re stable disease without adverse events, stable disease with adverse
vents, disease progression, and death. Transition probabilities were
stimated using a subset of the RECORD-1 patient population receiving
verolimus after sunitinib, and a comparable population receiving
orafenib in a single-arm phase II study. Costs of antitumor therapies
ere based onwholesale acquisition cost. Health state costs accounted
or physician visits, tests, adverse events, postprogression therapy, and O
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doi:10.1016/j.jval.2011.04.008nd-of-life care. The model extrapolated beyond the trial time horizon
or up to 6 years based on published trial data. Deterministic and prob-
bilistic sensitivity analyses were conducted. Results: The estimated
ain over sorafenib treatment was 1.273 LYs (0.916 QALYs) at an incre-
ental cost of $81,643. The deterministic analysis resulted in an incre-
ental cost-effectiveness ratio (ICER) of $64,155/LYG ($89,160/QALY).
he probabilistic sensitivity analysis demonstrated that results were
ighly consistent across simulations. Conclusions: As the ICER fell
ithin the cost per QALY range for many other widely used oncology
edicines, everolimus is projected to be a cost-effective treatment rel-
tive to sorafenib for sunitinib-refractory mRCC.
eywords: cost-effectiveness, everolimus, markov model, renal cell
arcinoma, vascular endothelial growth factor inhibitor.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Renal cell carcinoma (RCC) accounts for between 90% and 95% of
primary malignant renal tumors and is diagnosed in about 51,000
people per year in the United States [1]. The incidence rate has
been steadily increasing over the past 30 years [2]. Approximately
25% to 30% of patients present with metastases [3,4]. The eco-
nomic burden of RCC in the United States is substantial; studies
have estimated the annual cost of RCC andmRCC to be $4.4 billion
[5] and $107 to $556 million [6], respectively.
Over the past three years, targeted therapies, such as vascular
endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs)
(e.g., sunitinib and sorafenib) have become the standard over sys-
temic therapies such as interferon-alfa. In trials investigating the
efficacy of sunitinib and sorafenib, the incremental increase in
progression-free survival (PFS) ranged from 2.7 months [7] to 6
onths [8]. Although this is an improvement over previous ther-
pies, the disease still progresses eventually, thereby leaving a
ignificant unmet need for sequential treatment among RCC pa-
ients in whom VEGF-TKI therapy fails. Despite some concerns
bout following one therapy with another that shares a common
echanism of action (i.e., sorafenib following sunitinib), recent
* Address correspondence to: Roman Casciano, President, Analytic
E-mail: rcasciano@analyticaintl.com.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.iterature demonstrates that this treatment pattern has been and
s continuing to be investigated [9–11].
Everolimus was recently approved by the US Food and Drug
dministration as a once-daily, orally administered therapy for
he treatment of patients with advanced RCC after their disease
ails to respond to sunitinib or sorafenib treatment. Everolimus is
n inhibitor of mammalian target of rapamycin (mTOR), a compo-
ent of an intracellular signaling pathway that regulates cellularme-
abolism,growth,proliferation, andangiogenesis [12]. RECORD-1, the
ivotal, randomized, phase III trial of patientswithmRCCwhohad
rogressed on sunitinib, sorafenib, or both demonstrated a me-
ian PFS of 4.9 months (95% confidence interval [CI]: 4.0–5.5) for
verolimus-treated patients compared to 1.9 months (95% CI: 1.8–
.9) for the best supportive care (BSC) alone group (hazard ratio:
.33) [13,14]. Everolimus was evaluated against BSC alone because
hat was the standard of care at the time; that is, no other targeted
herapy was recommended.
Because there were no head-to-head trials comparing everoli-
us and sorafenib as second-line therapies, a recent indirect com-
arison study was conducted between a patient population that
ad received sorafenib after sunitinib in a single-arm phase II
tudy and a matched subset of the RECORD-1 patient population
15], which showed that everolimuswas associatedwith improved
ernational, 24 West 40th Street, Floor 8, New York, NY 10018 USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
847V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 4 6 – 8 5 1overall survival outcomes compared to patients treated with
sorafenib after sunitinib failed. Based on this indirect comparison,
this analysis examines the potential cost-effectiveness of everoli-
mus versus sorafenib therapy in this setting from a US payer per-
spective.
Methods
Model structure
AMarkovmodelwas developed inMicrosoft Excel (Microsoft Corp,
Redmond, WA) to simulate two hypothetical patient cohorts, one
treatedwith everolimus and the other treatedwith sorafenib, after
sunitinib treatment failed. The cohorts were modeled over a
6-year time horizon in 8-week cycles from the time of either
everolimus or sorafenib treatment initiation. Four health states
were included in themodel: stable diseasewith no adverse events,
stable disease with adverse events, progressed disease, and death
(Fig. 1).
All patients started in the stable diseasewith no adverse events
health state and moved to the other health states according to
transition probabilities obtained from analysis of patient-level
datawithin the RECORD-1 clinical trial and the single-armphase II
study of sorafenib [9,13]. During each modeling cycle (one cycle is
equal to 8 weeks to parallel the time period of assessment in the
trial); patients accumulated costs and utilities according to the
input assumptions for the values associated with time in each
health state. Adverse event (AE) status did not affect likelihood of
progression or death, but was used to calculate associated quality-
of-life reductions and increased costs. Patients could only advance
to amore severe health state and could not return to stable disease
once having progressed.
Cost inputs
In the RECORD-1 trial, patients received oral everolimus 10mg/day
continuously until disease progression or dose reduction/discon-
tinuation due to tolerance issues. In the single-arm phase II
Fig. 1 – Markov model health states. The Markov model sim
everolimus and the other sorafenib after sunitinib treatmen
with no adverse events, stable disease with adverse events,sorafenib study, patients received oral sorafenib 400 mg twicedaily until disease progression. The model used the patient-level
data to estimate the treatment dose intensity, which was esti-
mated to be 90% andwas calculated as the actual amount of treat-
ment taken by the entire study population divided by the expected
amount of treatment administered. The drug cost of everolimus
and sorafenib was based on 2010 wholesale acquisition cost and
was estimated to be $206.32 per day and $222.04 per day, respec-
tively (Table 1).
Direct medical costs for the stable disease health states in-
cluded routine follow-up (general practitioner visits, computed to-
mography scans, and blood tests) and the treatment of the most
common grade 3/4 AEs (viz., anemia, anorexia/cachexia, dyspnea,
fatigue, infections/infestations, lymphopenia, nausea/vomiting,
noninfectious pneumonitis, and thrombocytopenia) (Table 2). Re-
source use associated with AEs was based on National Compre-
hensive Cancer Network guidelines and published literature
[16–24]. The cost of treating AEs was a weighted average of the
component AEs of interest. It was assumed that in patients with
an AE, it had resolved within the first cycle of entering the stable
disease with AE health state and therefore, the cost of the AE
was applied during the first cycle of entering the health state,
after which, standard treatment costs for stable disease were
applied.
Within themodel, expected treatments for disease progression
included general practitioner visits, community nurse visits, pain
medications, and postdiscontinuation treatments. Postdiscon-
tinuation treatments (salvage therapies) consisted of active anti-
d two hypothetical patient cohorts, one treated with
ure. The model included four health states: stable disease
ase progression, and death.
Table 1 – Drug costs.
Drug Brand Dose and
frequency
Cost Cost per
8-week cycle
Everolimus Afinitor 10 mg/day $206 per dose* $10,399†
Sorafenib Nexavar 800 mg/day $222 per dose* $11,191†
* Drug unit costs from First DataBank Inc. [41].ulate
t fail
dise† Assumed a 90% dose intensity for both treatment arms.
gth of
848 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 4 6 – 8 5 1cancer agents, as given in the RECORD-1 trial post-progression.
The analysis incorporated a weighted average of postprogression
therapies (surgical, pharmacological, radiotherapeutic). Death
(termed an absorbing health state) was assigned the cost of end-
of-life care, whichwas based on secondary literature (Table 2) [25].
Indirect costs (e.g., lost productivity and cost to caregiver)were not
included in the model. Costs and outcomes were discounted at
3.0% annually.
Health utilities
Health utility scores (between 0  death and 1  perfect health)
were used to calculate quality-adjusted life-years (QALYs). As nei-
ther the RECORD-1 trial nor the single-arm phase II sorafenib
study included the EuroQoL for the assessment of utility, the
health state utility values used by PenTAG (in their UK analysis) to
evaluate sorafenib for second-line patients unsuitable for inter-
feron were adopted because those patients most closely resem-
bled the patient population under investigation [26]. All assumed
utility values are summarized in Table 3.
Base-case analysis
The effectiveness and costs for each hypothetical cohort were
evaluated and compared. Specifically, the analyses performed in-
cluded the total and incremental life-years gained (LYG), QALYs,
and costs for and between each cohort. The cost-effectiveness of
everolimus therapy was calculated in terms of costs per life-years
gained as well as cost per QALY gained [27].
Sensitivity analyses
One-way sensitivity analyses on parameters including costs, util-
ities, and probabilities were performed to identify key parameters
driving the resulting ICERs. Additionally, the robustness of the
resultswas evaluated by a probabilistic sensitivity analysis using a
second-order Monte Carlo simulation. Patient transition probabil-
ities and utility values followed a Dirichlet and beta distribution,
respectively [28]. The cost parameters were assumed to follow a
Table 2 – Nondrug costs.
Cost item Base-case
Monitoring $191 per general practitioner
Blood test $37 per test; 1 test per month
CT scans $2090 per scan; 1 scan every
Adverse events $906 (everolimus)§
$602.39 (sorafenib)§
BSC in PD $191 per general practitioner
$93 per community nurse vis
$0.65 per morphine sulfate d
Postdiscontinuation treatmen
$7774 weighted average
Death $8899¶
AE: adverse event; BSC: best supportive care; CPT: current procedura
* CPT Code 99,214: office visit and other outpatient services, establi
Coding Guide 2009) [41].
† CPT Code 85,027: complete (complete blood count), automated (hem
(American Medical Association. Physicians’ Fee and Coding Guide
‡ CPT Code 71,260: computed tomography, thorax, with contrastmat
Medical Association. Physicians’ Fee and Coding Guide 2009) [42].
§ Mean cost of treating treatment-related adverse events (anemia, an
nausea/vomiting, noninfectious pneumonitis, and thrombocytope
 CPTCode 99,211: office visits and other outpatient services, establish
and Coding Guide 2009) [42].
¶ Cost of final week of life, multiplied by 4 to estimate the final monamma distribution. The Monte Carlo simulation was run for 100iterations of 1000 patients. Results of the probabilistic sensitivity
analysis were used to generate cost-effectiveness acceptability
curves.
Results
The base-case results (Table 4) indicate a difference of $81,643 in
the total average per-patient cost of treatment with everolimus
versus sorafenib, 80% of which is composed of drug acquisition
costs. Patients on everolimus had estimated gains in LYs and
QALYs over sorafenib of 1.273 and 0.916, respectively (Table 4).
This resulted in an incremental cost-effectiveness ratio of $64,155/
LYG or $89,160/QALY.
Results from the one-way sensitivity analysis on key parame-
ters of the deterministic model are summarized in Table 5. First,
post-discontinuation treatments were one of the main drivers in
the model, the absence of which resulted in an ICER of $77,897/
QALY. Additionally, increasing the treatment dose intensity to
100% for both comparators subsequently increased the ICER to
$97,103/QALY. Assuming thatmortality rate after disease progres-
sion would be the same for both treatment arms, treatment with
everolimus would be associated with prolonged survival of 0.669
life-years (1.805 life-years for everolimus vs. 1.136 life-years for
sorafenib) or 0.505 QALYs (1.298 QALYs for everolimus vs. 0.793
Table 3 – Health state utility values.
Health state Utility (SD)
Stable disease with no adverse events 0.76 (0.03)*
Stable disease with adverse events 0.71†(0.04)‡
Progressed disease 0.68 (0.04)*
Death 0.00 (0.00)*
* PenTAG Report 2008 [26].
† 0.05 disutility associated with dyspnea.
t Cost per 8-week cycle
1 visit per month* $381
$74
ths‡ $697
$906 (everolimus)
$602.39 (sorafenib)
1 visit per month* $6330
visits per month
ne dose daily
alvage therapy),
$8899
inology; CT, computed tomography; PD: progressed disease.
patient level 4; (American Medical Association. Physicians’ Fee and
ing, hematocrit, red blood cells, white blood cells, and platelet count)
[42].
; CPT Code 72,193: lumbar CT scanwith contrastmaterials (American
ia/cachexia, dyspnea, fatigue, infections/infestations, lymphopenia,
tient; level 1 (nurses) (AmericanMedical Association. Physicians’ Fee
life; inflated to 2010 USD [43].cos
visit;
†
6 mon
visit;
it; 1.5
ose; o
ts (s
l term
shed
oglob
2009)
erials
orex
nia).
ed pa‡ Doyle et al. [44].
849V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 4 6 – 8 5 1QALYs for sorafenib). The survival benefit was associated with an
incremental cost of $57,006, resulting in an ICER of $112,807/QALY
(Table 5).
Simulating a cohort of 1000 patients for 100 iterations, the
probabilistic sensitivity analysis reported results that were
highly consistent with the base-case analysis. The mean life-
year gained was 1.409 LYG, whereas the mean QALY was 1.028.
The mean incremental cost per life-year gained and cost per
QALY for everolimus compared to sorafenib were $55,565/LYG
and $76,496/QALY, respectively. Over the course of 100 itera-
tions, the ICER ranged between $60,138/QALY and $90,671/
QALY. According to the cost-effectiveness acceptability curve,
the probability that the ICER falls below $70,000/QALY, $80,000/
QALY, and $90,000/QALY is 15.8%, 68.3%, and 98.0%, respec-
tively (Fig. 2).
Discussion
Although treatment of mRCC patients post-failure on VEGF-TKI
therapywith everolimushas proved to be clinically efficacious, the
model results indicate that it is also likely to be cost-effective
when compared to sorafenib treatment. Specifically, when com-
Table 4 – Base-case deterministic results.
Everolimus Sorafenib Incremental
Life-years 1.805 0.533 1.273
QALYs 1.298 0.382 0.916
Drug cost $85,172 $19,711 $65,460
Total costs $124,379 $42,736 $81,643
ICERs
Cost/life-years
gained
$64,155
Cost/QALY $89,160
ICERs, incremental cost-effectiveness ratios; QALY, quality-ad-
justed life-year.
Table 5 – One-way sensitivity analysis results.
Base case
Base case N/A
General
Discounting (costs and benefits) 3.0%
Costs
Associated with death $8899
CT scan $2090
AE cost $906 (everolimus)
$602 (sorafenib)
Postdiscontinuation treatment $5598
Active treatment dose intensity 90%
Health state utilities
PFS 0.76
PD 0.68
Transition probability
Postprogression mortality Everolimus and
sorafenib
probabilities
differed
AE, adverse event; CT, computed tomography; ICER: incremental cost
QALY, quality-adjusted life-year.pared to sorafenib, the survival benefits of everolimus would be
attained at a cost of $64,155/LYG or $89,160/QALY. As is typical of
cost-effectiveness analyses in oncology settings, the ICER is highly
sensitive to changes in the differences between the costs and the
mortality rates of the two comparators because these values dom-
inate the numerator and the denominator of the ICER. It is impor-
tant to point out, however, that the results of this analysis were
robust to changes in the parameters for which the highest level of
uncertainty exists (Table 5). Among these factors, postprogression
mortality, postdiscontinuation treatment cost, and dose intensity
of the active treatments are themost notable and had the greatest
impact on the cost-effectiveness ratio. Although, in general, wide
variations in utility values could result in considerable variations
in the ICER, the confidence intervals around the point estimates
were narrow (Table 5). Overall, when compared to treatment with
sorafenib, everolimus has a very high probability of being consid-
ered cost-effective at a willingness-to-pay threshold of $100,000/
QALY or more.
The conclusions drawn from this prospective economic analy-
sis should be viewed in light of several limitations. Results may
not be easily generalized to all RCC patients given that the proba-
bilities used in the model are taken from clinical trials. As in all
clinical trials, the RECORD-1 and the single-arm phase II sorafenib
study used inclusion/exclusion criteria resulting in a sample that
will differ somewhat from the ultimate real-world population. The
analysis herein also extrapolated outcomes beyond the length of
the clinical trial. Because there is uncertainty regarding the actual
6-year survival that will be achieved by this patient population,
the incremental cost-effectiveness of everolimus may vary from
the results presented. It is also important to note that the model
accounts for AE costs in a manner that is likely biased against
everolimus in comparison to sorafenib. The model did not incor-
porate the AE rates from the single-arm phase II study (which
formed the basis of the efficacy assumptions herein) because they
were extremely highwhen compared to those reported for everoli-
mus in the phase III RECORD-1 study. The large difference in AE
incidence between the two studies may be due to the general dif-
ferences between a phase II and a phase III study population with
Sensitivity analysis ICER (cost/QALY)
(everolimus vs. sorafenib)
N/A $89,160
0% $89,579
$0 $90,026
$0 $86,785
$0 (both treatment arms) $88,928
$0 $77,897
100% $97,103
0.70 (lower 95% CI) $91,640
0.81 (upper 95% CI) $87,193
0.61 (lower 95% CI) $91,134
0.76 (upper 95% CI) $87,005
Sorafenib arm transition
probabilities set equal
to that of the
everolimus arm
$112,807
tiveness ratio; PD, progressed disease; PFS, progression-free survival;-effec
i
t
850 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 4 6 – 8 5 1respect to the rigor of inclusion/exclusion criteria and differences
in the documentation of adverse events. To be conservative, the
AEs considered for both agents in the model are based on their
respective full prescribing information [12,29]. Although the
everolimus prescribing information reported theAE rates from the
phase III RECORD-1 study, the sorafenib prescribing information
provided AE rates for a population that was earlier in the course of
the disease than those represented in the single-arm phase II
study.
Although head-to-head comparisons between treatments are
preferred, currently there are no such published analyses for
everolimus versus sorafenib. Although indirect comparisons are
an accepted methodology, study findings must be interpreted as
associations because the participation in particular studies or at
particular centers is not random between arms being compared.
Additionally, indirect analyses carry inherent limitations [30]. To
preciselymatch the study populations, the groups’ characteristics
should be fully parallel, but in this analysis, there were residual
confounders. Although the populations were matched on previ-
ous treatment, clear-cell histology, Memorial Sloan-Kettering
Cancer Center risk score, and Eastern Cooperative Oncology Group
(ECOG) performance status, or Karnofsky Performance Status
score, these two populations were still slightly different from each
other after matching. A small difference in ECOG performance
status persisted because the RECORD-1 study excluded patients
with an ECOG performance status of 2 or higher, whereas the
phase II sorafenib study did not. Although the sorafenib popula-
tion included only 6.7% of patients at these levels, the difference
in ECOG performance status biased the analysis in favor of
everolimus. In contrast, a higher proportion of patients in the
RECORD-1 study received previous immunotherapy (i.e., inter-
feron-alfa, interleukin-2, and previous radiotherapy), which
may indicate that their disease was more advanced at the time
of the study. This difference may bias against everolimus. In
light of these discrepancies, the net direction of the bias cannot
be clearly determined.
Additionally, when comparing the median overall survival
for patients in the sorafenib arm to that of patients randomized
to BSC alone in the RECORD-1 trial, the results first appear to be
counterintuitive: results from a rank-preserving structural fail-
Fig. 2 – The cost-effectiveness acceptability curve illustrates
ratio decreases to less than $70,000/QALY, $80,000/QALY, anure time (RPSFT) analysis [31] imply that patients receiving BSC malone live longer than those who received sorafenib in the sin-
gle-arm phase II sorafenib study. It must be noted, however,
that the results are a point estimate of the RPSFT analysis and
that there is a wide confidence interval around this estimate.
The lower bound of the estimate indicates that patients receiv-
ing BSC have shorter overall survival than those receiving
sorafenib in the single-arm phase II study [32]. Further research
is required to determine the long-term survival for sunitinib-
refractory patients receiving everolimus and sorafenib treat-
ments. The results of this study should also be interpreted with
the understanding that they depend on the selected utility val-
ues. There is variability in health state utility values among
patients as well as across available utility studies. This analysis
relied on the values from the PenTAG study, although other
studies have reportedmore conservative (i.e., lower) health util-
ity values [33]. The limitation, however, likely applies evenly to
both arms. As noted previously, results from the sensitivity
analysis, which tested the upper and lower bounds of the utility
values, indicate that this variability did not affect the overall
results qualitatively.
There is much debate over the use of benchmarks or willing-
ness-to-pay thresholds in health-care economic analyses [34–37].
Thresholds of 50,000/QALY [35] or 100,000/QALY [38] have been
proposed; however, their use suggests that economic efficiency is
of paramount concern to decision makers. Many economists
would argue that the threshold should bemuchhigher on average:
Murphy and Topel [39] estimate the value peaks at $350,000 per LY
for a 50-year-old person, but decreases with age: their estimate is
about $300,000 at age 60 and $250,000 at age 70. It only falls below
$100,000 at approximately age 95.
It is important to consider that cost-effectiveness may soon
be taken into account when health plans evaluate drugs for tier
placement. For example, Premera Blue Cross is developing a
formulary plan that will implement a tier-based schedule based
on cost per QALY. This policy is aimed to take full effect be-
tween 2013 and 2015 [40]. Although further study is warranted
n broader populations, providers and decision makers should
ake these results into consideration when treating appropriate
the probability that the incremental cost-effectiveness
0,000/QALY is 15.8%, 68.3%, and 98.0%, respectively.that
d $9RCC patients.
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